| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 30 | 2024 | 130 | 6.190 |
Why?
|
| Cadherins | 14 | 2024 | 178 | 5.240 |
Why?
|
| Lupus Erythematosus, Systemic | 10 | 2025 | 226 | 3.070 |
Why?
|
| Arthritis, Rheumatoid | 15 | 2026 | 286 | 2.750 |
Why?
|
| Antirheumatic Agents | 8 | 2026 | 118 | 2.260 |
Why?
|
| Macrophages | 5 | 2024 | 666 | 1.760 |
Why?
|
| Skin | 7 | 2024 | 553 | 1.490 |
Why?
|
| Autoantibodies | 11 | 2019 | 466 | 1.330 |
Why?
|
| Skin Diseases | 3 | 2018 | 141 | 1.120 |
Why?
|
| Pulmonary Fibrosis | 4 | 2022 | 115 | 1.120 |
Why?
|
| Autoimmune Diseases | 7 | 2024 | 275 | 1.110 |
Why?
|
| Transforming Growth Factor beta | 7 | 2019 | 463 | 1.090 |
Why?
|
| Fibroblasts | 11 | 2024 | 864 | 1.090 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2024 | 3412 | 1.080 |
Why?
|
| Disease Models, Animal | 14 | 2025 | 4696 | 1.050 |
Why?
|
| Rheumatic Diseases | 5 | 2024 | 78 | 1.000 |
Why?
|
| Fibrosis | 9 | 2024 | 414 | 1.000 |
Why?
|
| Synovitis | 2 | 2020 | 24 | 0.910 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 233 | 0.890 |
Why?
|
| Lung Diseases, Interstitial | 6 | 2024 | 176 | 0.880 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2025 | 256 | 0.860 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 111 | 0.850 |
Why?
|
| Dendritic Cells | 3 | 2024 | 438 | 0.820 |
Why?
|
| Phagocytosis | 2 | 2024 | 191 | 0.790 |
Why?
|
| Liver | 2 | 2022 | 1799 | 0.790 |
Why?
|
| Medication Adherence | 1 | 2026 | 334 | 0.740 |
Why?
|
| Extracellular Matrix | 4 | 2019 | 231 | 0.730 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2022 | 15 | 0.730 |
Why?
|
| Machine Learning | 1 | 2026 | 375 | 0.730 |
Why?
|
| Patient Compliance | 1 | 2024 | 469 | 0.680 |
Why?
|
| Genome-Wide Association Study | 6 | 2024 | 1840 | 0.680 |
Why?
|
| Papillomavirus Infections | 1 | 2025 | 389 | 0.680 |
Why?
|
| Kava | 1 | 2020 | 8 | 0.670 |
Why?
|
| Uveitis | 1 | 2020 | 33 | 0.660 |
Why?
|
| Sarcoidosis | 1 | 2020 | 52 | 0.650 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 501 | 0.650 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 418 | 0.640 |
Why?
|
| Arthritis | 1 | 2020 | 85 | 0.640 |
Why?
|
| Vaccination | 1 | 2025 | 1040 | 0.630 |
Why?
|
| Myofibroblasts | 3 | 2019 | 62 | 0.630 |
Why?
|
| Monocytes | 1 | 2022 | 337 | 0.630 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 74 | 0.620 |
Why?
|
| Rheumatology | 4 | 2024 | 128 | 0.610 |
Why?
|
| Osteoarthropathy, Primary Hypertrophic | 1 | 2019 | 2 | 0.610 |
Why?
|
| Bleomycin | 7 | 2024 | 111 | 0.590 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2015 | 140 | 0.590 |
Why?
|
| Naphthols | 1 | 2018 | 9 | 0.580 |
Why?
|
| Medical History Taking | 1 | 2019 | 109 | 0.580 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2017 | 2862 | 0.570 |
Why?
|
| Watchful Waiting | 1 | 2019 | 74 | 0.560 |
Why?
|
| Humans | 72 | 2026 | 131604 | 0.560 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 1010 | 0.530 |
Why?
|
| Sulfonamides | 2 | 2024 | 296 | 0.530 |
Why?
|
| Mice | 21 | 2025 | 18486 | 0.530 |
Why?
|
| Immunologic Factors | 2 | 2011 | 192 | 0.530 |
Why?
|
| Animals | 27 | 2025 | 34371 | 0.520 |
Why?
|
| Autoimmunity | 2 | 2024 | 182 | 0.500 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2016 | 13 | 0.490 |
Why?
|
| Strongyloides stercoralis | 1 | 2016 | 24 | 0.480 |
Why?
|
| Strongyloidiasis | 1 | 2016 | 51 | 0.470 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 138 | 0.460 |
Why?
|
| Mice, Knockout | 8 | 2024 | 3864 | 0.440 |
Why?
|
| Cell Differentiation | 3 | 2022 | 1947 | 0.440 |
Why?
|
| Inflammation | 3 | 2024 | 1492 | 0.420 |
Why?
|
| Female | 36 | 2026 | 71145 | 0.400 |
Why?
|
| Cell Adhesion | 4 | 2022 | 312 | 0.390 |
Why?
|
| Hypertension, Pulmonary | 3 | 2023 | 463 | 0.380 |
Why?
|
| Hemorrhage | 1 | 2016 | 498 | 0.370 |
Why?
|
| Mice, Inbred C57BL | 11 | 2024 | 4769 | 0.360 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 901 | 0.360 |
Why?
|
| Rheumatoid Factor | 1 | 2011 | 6 | 0.360 |
Why?
|
| Osteopontin | 1 | 2012 | 51 | 0.360 |
Why?
|
| HLA Antigens | 4 | 2024 | 229 | 0.360 |
Why?
|
| Cytokines | 6 | 2019 | 1347 | 0.360 |
Why?
|
| Managed Care Programs | 1 | 2011 | 56 | 0.350 |
Why?
|
| CD58 Antigens | 1 | 2011 | 7 | 0.350 |
Why?
|
| Epithelial Cells | 1 | 2015 | 900 | 0.340 |
Why?
|
| CD11b Antigen | 1 | 2011 | 35 | 0.340 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2011 | 20 | 0.340 |
Why?
|
| Male | 36 | 2026 | 65228 | 0.340 |
Why?
|
| CD11c Antigen | 1 | 2011 | 40 | 0.340 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 3834 | 0.330 |
Why?
|
| Genetic Loci | 2 | 2011 | 359 | 0.320 |
Why?
|
| Cells, Cultured | 7 | 2019 | 2971 | 0.320 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 3094 | 0.320 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 22 | 0.310 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 262 | 0.310 |
Why?
|
| OX40 Ligand | 1 | 2009 | 9 | 0.310 |
Why?
|
| Receptors, Interleukin | 1 | 2009 | 37 | 0.310 |
Why?
|
| Middle Aged | 19 | 2025 | 28883 | 0.310 |
Why?
|
| Interferon-alpha | 1 | 2011 | 241 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 902 | 0.280 |
Why?
|
| Synovial Fluid | 1 | 2008 | 17 | 0.280 |
Why?
|
| Lung | 2 | 2015 | 1565 | 0.280 |
Why?
|
| Withholding Treatment | 1 | 2008 | 76 | 0.270 |
Why?
|
| Cell Communication | 2 | 2008 | 196 | 0.270 |
Why?
|
| Stress, Psychological | 2 | 2011 | 562 | 0.270 |
Why?
|
| Glucocorticoids | 3 | 2024 | 350 | 0.270 |
Why?
|
| Cyclosporine | 2 | 2025 | 129 | 0.270 |
Why?
|
| Myositis | 2 | 2024 | 106 | 0.260 |
Why?
|
| United States | 9 | 2026 | 11800 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 643 | 0.250 |
Why?
|
| Interferon Regulatory Factor-7 | 2 | 2019 | 9 | 0.250 |
Why?
|
| Adult | 17 | 2025 | 31702 | 0.240 |
Why?
|
| Antigens, CD | 1 | 2008 | 418 | 0.240 |
Why?
|
| Hospitals, University | 1 | 2005 | 103 | 0.230 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 227 | 0.220 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2024 | 11 | 0.210 |
Why?
|
| Phagocytes | 1 | 2024 | 25 | 0.210 |
Why?
|
| Immunosuppressive Agents | 2 | 2025 | 667 | 0.210 |
Why?
|
| Terpenes | 1 | 2024 | 32 | 0.210 |
Why?
|
| Vascular Diseases | 1 | 2025 | 155 | 0.210 |
Why?
|
| Lymph Nodes | 1 | 2025 | 376 | 0.200 |
Why?
|
| Lipoblastoma | 1 | 2023 | 6 | 0.200 |
Why?
|
| B-Lymphocytes | 2 | 2019 | 529 | 0.200 |
Why?
|
| Myeloid Cells | 1 | 2024 | 115 | 0.200 |
Why?
|
| Liposomes | 1 | 2024 | 200 | 0.200 |
Why?
|
| Macrophages, Alveolar | 2 | 2014 | 49 | 0.200 |
Why?
|
| Genotype | 6 | 2011 | 2655 | 0.190 |
Why?
|
| Young Adult | 4 | 2025 | 10094 | 0.190 |
Why?
|
| Dermatologic Agents | 1 | 2023 | 31 | 0.190 |
Why?
|
| Psoriasis | 1 | 2023 | 52 | 0.190 |
Why?
|
| Medicare | 1 | 2026 | 437 | 0.190 |
Why?
|
| Collagen | 3 | 2019 | 289 | 0.190 |
Why?
|
| Antigens, Ly | 1 | 2022 | 33 | 0.180 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 128 | 0.180 |
Why?
|
| Nanoparticles | 2 | 2025 | 292 | 0.180 |
Why?
|
| Antibodies, Antinuclear | 2 | 2011 | 31 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 10 | 0.180 |
Why?
|
| Myoclonus | 1 | 2021 | 32 | 0.170 |
Why?
|
| Biological Products | 1 | 2023 | 144 | 0.170 |
Why?
|
| Polymorphism, Genetic | 1 | 2024 | 794 | 0.170 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2020 | 11 | 0.170 |
Why?
|
| Encephalitis | 1 | 2021 | 120 | 0.160 |
Why?
|
| Vitamin D | 2 | 2019 | 194 | 0.160 |
Why?
|
| Signal Transduction | 6 | 2019 | 4683 | 0.160 |
Why?
|
| Glomerulonephritis | 1 | 2020 | 75 | 0.160 |
Why?
|
| Carbon Tetrachloride | 1 | 2019 | 6 | 0.150 |
Why?
|
| Hepatic Stellate Cells | 1 | 2019 | 28 | 0.150 |
Why?
|
| Iron, Dietary | 1 | 2019 | 15 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 470 | 0.150 |
Why?
|
| Cohort Studies | 6 | 2017 | 5123 | 0.150 |
Why?
|
| Disease Progression | 4 | 2024 | 2206 | 0.150 |
Why?
|
| Case-Control Studies | 7 | 2023 | 3454 | 0.150 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 209 | 0.150 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2018 | 3 | 0.150 |
Why?
|
| Vitamins | 1 | 2019 | 115 | 0.140 |
Why?
|
| Muromegalovirus | 1 | 2017 | 12 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 775 | 0.140 |
Why?
|
| Hepatocytes | 1 | 2019 | 234 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 444 | 0.130 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 59 | 0.130 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 78 | 0.130 |
Why?
|
| Apoptosis | 1 | 2024 | 1861 | 0.130 |
Why?
|
| Ustekinumab | 1 | 2017 | 3 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 114 | 0.130 |
Why?
|
| Arthralgia | 1 | 2017 | 77 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 159 | 0.130 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 266 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2026 | 17666 | 0.130 |
Why?
|
| Synovial Membrane | 2 | 2007 | 27 | 0.130 |
Why?
|
| Aged | 7 | 2026 | 21255 | 0.120 |
Why?
|
| Killer Cells, Natural | 2 | 2017 | 344 | 0.120 |
Why?
|
| Herpesviridae Infections | 1 | 2017 | 139 | 0.120 |
Why?
|
| Aged, 80 and over | 2 | 2026 | 6922 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2019 | 358 | 0.120 |
Why?
|
| Dermis | 2 | 2016 | 28 | 0.120 |
Why?
|
| Up-Regulation | 3 | 2019 | 832 | 0.120 |
Why?
|
| Mice, 129 Strain | 2 | 2014 | 97 | 0.110 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2011 | 83 | 0.110 |
Why?
|
| Methotrexate | 3 | 2023 | 342 | 0.110 |
Why?
|
| Biomarkers | 5 | 2022 | 3405 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2010 | 1833 | 0.110 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2014 | 40 | 0.110 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 1418 | 0.110 |
Why?
|
| Prognosis | 3 | 2019 | 4952 | 0.100 |
Why?
|
| Platelet Factor 4 | 1 | 2013 | 22 | 0.100 |
Why?
|
| Biopsy | 1 | 2017 | 1252 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2010 | 1008 | 0.100 |
Why?
|
| Mice, Inbred MRL lpr | 2 | 2025 | 17 | 0.100 |
Why?
|
| Child | 3 | 2024 | 26250 | 0.100 |
Why?
|
| Epistasis, Genetic | 2 | 2010 | 98 | 0.100 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2014 | 185 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2017 | 353 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2014 | 419 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2025 | 1625 | 0.090 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 46 | 0.090 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2011 | 13 | 0.090 |
Why?
|
| Smad2 Protein | 1 | 2012 | 55 | 0.090 |
Why?
|
| Transcriptome | 1 | 2019 | 1163 | 0.090 |
Why?
|
| Genetic Markers | 2 | 2011 | 605 | 0.090 |
Why?
|
| Histocompatibility Testing | 2 | 2009 | 109 | 0.090 |
Why?
|
| Stress Disorders, Traumatic | 1 | 2011 | 7 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 125 | 0.090 |
Why?
|
| Neurosecretory Systems | 1 | 2011 | 23 | 0.080 |
Why?
|
| France | 1 | 2011 | 89 | 0.080 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2010 | 6 | 0.080 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2010 | 14 | 0.080 |
Why?
|
| Adolescent | 4 | 2024 | 20931 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2082 | 0.080 |
Why?
|
| Cell Movement | 1 | 2014 | 881 | 0.080 |
Why?
|
| STAT4 Transcription Factor | 1 | 2009 | 11 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2010 | 90 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 227 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2023 | 12964 | 0.080 |
Why?
|
| Interleukin-23 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 1169 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2024 | 794 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 140 | 0.080 |
Why?
|
| Centromere | 1 | 2009 | 69 | 0.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 205 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 95 | 0.080 |
Why?
|
| Genetic Association Studies | 2 | 2010 | 837 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2009 | 92 | 0.070 |
Why?
|
| Interferons | 1 | 2010 | 136 | 0.070 |
Why?
|
| Interleukin-17 | 1 | 2009 | 128 | 0.070 |
Why?
|
| Leukocytes | 2 | 2010 | 211 | 0.070 |
Why?
|
| T-Box Domain Proteins | 1 | 2009 | 116 | 0.070 |
Why?
|
| Neoplasms | 2 | 2023 | 2969 | 0.070 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 23 | 0.070 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 318 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 530 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2008 | 118 | 0.070 |
Why?
|
| Mass Screening | 2 | 2024 | 825 | 0.070 |
Why?
|
| Alleles | 2 | 2011 | 1708 | 0.070 |
Why?
|
| Social Support | 1 | 2011 | 374 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 2297 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2023 | 665 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 792 | 0.070 |
Why?
|
| Epitopes | 1 | 2009 | 432 | 0.070 |
Why?
|
| Risk Factors | 4 | 2011 | 10959 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1610 | 0.070 |
Why?
|
| Family | 1 | 2010 | 589 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1139 | 0.060 |
Why?
|
| Mutation | 1 | 2020 | 6177 | 0.060 |
Why?
|
| Cell Line | 1 | 2011 | 2605 | 0.060 |
Why?
|
| Adherens Junctions | 1 | 2006 | 17 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2023 | 1634 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 387 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2120 | 0.060 |
Why?
|
| Massachusetts | 1 | 2005 | 118 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 577 | 0.060 |
Why?
|
| Infliximab | 1 | 2005 | 66 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2005 | 78 | 0.060 |
Why?
|
| Vital Capacity | 2 | 2017 | 89 | 0.060 |
Why?
|
| rho-Associated Kinases | 2 | 2016 | 48 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2648 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3615 | 0.060 |
Why?
|
| Lipids | 1 | 2008 | 565 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2005 | 164 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 1306 | 0.050 |
Why?
|
| Gene Frequency | 3 | 2011 | 750 | 0.050 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2024 | 4 | 0.050 |
Why?
|
| Peptides | 1 | 2008 | 835 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2022 | 6494 | 0.050 |
Why?
|
| Walk Test | 1 | 2024 | 30 | 0.050 |
Why?
|
| Phenotype | 2 | 2011 | 4516 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2024 | 20 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 741 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2008 | 423 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2011 | 667 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2024 | 220 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 173 | 0.050 |
Why?
|
| Mesentery | 1 | 2023 | 28 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2024 | 282 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 99 | 0.050 |
Why?
|
| Sjogren's Syndrome | 1 | 2024 | 108 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2022 | 76 | 0.050 |
Why?
|
| Blood Sedimentation | 1 | 2022 | 26 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 230 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2003 | 108 | 0.050 |
Why?
|
| Tretinoin | 1 | 2022 | 97 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2008 | 553 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2023 | 211 | 0.040 |
Why?
|
| Recurrence | 1 | 2005 | 1483 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2022 | 158 | 0.040 |
Why?
|
| RNA Interference | 1 | 2023 | 496 | 0.040 |
Why?
|
| Actins | 2 | 2017 | 317 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2024 | 644 | 0.040 |
Why?
|
| Lymphatic System | 1 | 2020 | 19 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 517 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2023 | 357 | 0.040 |
Why?
|
| Europe | 2 | 2011 | 372 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2003 | 435 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 364 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 455 | 0.040 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Smad3 Protein | 1 | 2019 | 56 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2022 | 536 | 0.040 |
Why?
|
| Granzymes | 1 | 2017 | 47 | 0.030 |
Why?
|
| Deoxyglucose | 1 | 2017 | 42 | 0.030 |
Why?
|
| Androstadienes | 1 | 2017 | 50 | 0.030 |
Why?
|
| Mastectomy | 1 | 2017 | 75 | 0.030 |
Why?
|
| Virus Activation | 1 | 2017 | 86 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2019 | 296 | 0.030 |
Why?
|
| Interleukin-15 | 1 | 2017 | 102 | 0.030 |
Why?
|
| Glycolysis | 1 | 2017 | 171 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 87 | 0.030 |
Why?
|
| Physicians | 1 | 2003 | 634 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 327 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2016 | 32 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 259 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2016 | 46 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 393 | 0.030 |
Why?
|
| Elastin | 1 | 2016 | 32 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 420 | 0.030 |
Why?
|
| Viral Load | 1 | 2017 | 406 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 225 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 542 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 265 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 693 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 382 | 0.030 |
Why?
|
| Fibronectins | 1 | 2014 | 99 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 67 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 18 | 0.030 |
Why?
|
| Muscle Development | 1 | 2014 | 71 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1405 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2014 | 154 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 138 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2013 | 49 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2017 | 1104 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2013 | 50 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1516 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 589 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2016 | 692 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2014 | 249 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 232 | 0.020 |
Why?
|
| Proteins | 1 | 2017 | 1027 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2017 | 812 | 0.020 |
Why?
|
| Proteome | 1 | 2013 | 286 | 0.020 |
Why?
|
| Immunogenetics | 1 | 2011 | 10 | 0.020 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 47 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 1392 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3917 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2463 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 632 | 0.020 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 1 | 2010 | 2 | 0.020 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2010 | 12 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1226 | 0.020 |
Why?
|
| Spain | 1 | 2009 | 62 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2009 | 32 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 1501 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2013 | 368 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2010 | 106 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 79 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2009 | 186 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2009 | 156 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2008 | 73 | 0.020 |
Why?
|
| Phagosomes | 1 | 2008 | 37 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2567 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 543 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13305 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1521 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 449 | 0.020 |
Why?
|
| Arthritis, Experimental | 1 | 2007 | 20 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2023 | 15054 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 1595 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 1235 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2151 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 144 | 0.020 |
Why?
|
| Vinculin | 1 | 2006 | 7 | 0.020 |
Why?
|
| Reticulin | 1 | 2006 | 8 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 1101 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2006 | 64 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2008 | 464 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 1599 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 960 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2010 | 1556 | 0.010 |
Why?
|
| Affect | 1 | 2003 | 170 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5296 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 955 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 1788 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2003 | 1344 | 0.010 |
Why?
|
| Texas | 1 | 2003 | 3615 | 0.010 |
Why?
|